These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 8766632

  • 21. Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate.
    Palacpac NM, Arisue N, Tougan T, Ishii KJ, Horii T.
    Vaccine; 2011 Aug 11; 29(35):5837-45. PubMed ID: 21718740
    [Abstract] [Full Text] [Related]

  • 22. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction.
    Hermsen CC, de Vlas SJ, van Gemert GJ, Telgt DS, Verhage DF, Sauerwein RW.
    Am J Trop Med Hyg; 2004 Aug 11; 71(2):196-201. PubMed ID: 15306710
    [Abstract] [Full Text] [Related]

  • 23. Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
    Breman JG, Alilio MS, Mills A.
    Am J Trop Med Hyg; 2004 Aug 11; 71(2 Suppl):1-15. PubMed ID: 15331814
    [Abstract] [Full Text] [Related]

  • 24. [Antimalarial vaccination].
    Ambroise-Thomas P.
    Sante; 1995 Aug 11; 5(6):411-5. PubMed ID: 8784551
    [Abstract] [Full Text] [Related]

  • 25. Malaria vaccine offers hope. International / Africa.
    Vaccine Wkly; 1995 Mar 13; ():10-1. PubMed ID: 12288959
    [Abstract] [Full Text] [Related]

  • 26. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36.
    Horii T, Shirai H, Jie L, Ishii KJ, Palacpac NQ, Tougan T, Hato M, Ohta N, Bobogare A, Arakaki N, Matsumoto Y, Namazue J, Ishikawa T, Ueda S, Takahashi M.
    Parasitol Int; 2010 Sep 13; 59(3):380-6. PubMed ID: 20493274
    [Abstract] [Full Text] [Related]

  • 27. Progress on vaccines against parasites.
    Engers HD, Bergquist R, Modabber F.
    Dev Biol Stand; 1996 Sep 13; 87():73-84. PubMed ID: 8854004
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
    Flueck C, Frank G, Smith T, Jafarshad A, Nebie I, Sirima SB, Olugbile S, Alonso P, Tanner M, Druilhe P, Felger I, Corradin G.
    Vaccine; 2009 May 05; 27(20):2653-61. PubMed ID: 19428875
    [Abstract] [Full Text] [Related]

  • 29. Malaria vaccine: a current perspective.
    Sharma S, Pathak S.
    J Vector Borne Dis; 2008 Mar 05; 45(1):1-20. PubMed ID: 18399312
    [Abstract] [Full Text] [Related]

  • 30. Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria.
    Walther M.
    Expert Rev Vaccines; 2006 Feb 05; 5(1):81-93. PubMed ID: 16451110
    [Abstract] [Full Text] [Related]

  • 31. [The malaria vaccine candidate RTS,S/AS is in phase III clinical trials].
    Cohen J, Benns S, Vekemans J, Leach A.
    Ann Pharm Fr; 2010 Nov 05; 68(6):370-9. PubMed ID: 21073995
    [Abstract] [Full Text] [Related]

  • 32. Evidence of HLA class II association with antibody response against the malaria vaccine SPF66 in a naturally exposed population.
    Beck HP, Felger I, Barker M, Bugawan T, Genton B, Alexander N, Jazwinska E, Erlich H, Alpers M.
    Am J Trop Med Hyg; 1995 Sep 05; 53(3):284-8. PubMed ID: 7573714
    [Abstract] [Full Text] [Related]

  • 33. The Plasmodium sporozoite survives RTS,S vaccination.
    Snounou G, Grüner AC, Müller-Graf CD, Mazier D, Rénia L.
    Trends Parasitol; 2005 Oct 05; 21(10):456-61. PubMed ID: 16109504
    [Abstract] [Full Text] [Related]

  • 34. Functional analysis of Plasmodium falciparum merozoite antigens: implications for erythrocyte invasion and vaccine development.
    Cowman AF, Baldi DL, Duraisingh M, Healer J, Mills KE, O'Donnell RA, Thompson J, Triglia T, Wickham ME, Crabb BS.
    Philos Trans R Soc Lond B Biol Sci; 2002 Jan 29; 357(1417):25-33. PubMed ID: 11839179
    [Abstract] [Full Text] [Related]

  • 35. Vaccinating with the genome: a Sisyphean task?
    Coppel RL.
    Trends Parasitol; 2009 May 29; 25(5):205-12. PubMed ID: 19359219
    [Abstract] [Full Text] [Related]

  • 36. A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design.
    Alonso PL, Tanner M, Smith T, Hayes RJ, Schellenberg JA, Lopez MC, Bastos de Azevedo I, Menendez C, Lyimo E, Weiss N.
    Vaccine; 1994 Feb 29; 12(2):181-6. PubMed ID: 8147101
    [Abstract] [Full Text] [Related]

  • 37. [Malaria: from genetic and molecular biology to disease control].
    Ambroise-Thomas P.
    J Soc Biol; 2004 Feb 29; 198(3):181-5. PubMed ID: 15662933
    [Abstract] [Full Text] [Related]

  • 38. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia.
    Valero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murillo LA, Mora AL, Patarroyo G, Rocha CL, Rojas M.
    Lancet; 1993 Mar 20; 341(8847):705-10. PubMed ID: 8095622
    [Abstract] [Full Text] [Related]

  • 39. Asexual blood-stage malaria vaccine development: facing the challenges.
    Genton B, Reed ZH.
    Curr Opin Infect Dis; 2007 Oct 20; 20(5):467-75. PubMed ID: 17762779
    [Abstract] [Full Text] [Related]

  • 40. [Achievements and problems in the development of malaria vaccines].
    Martínez-Gómez F.
    Rev Latinoam Microbiol; 1993 Oct 20; 35(3):319-25. PubMed ID: 8047736
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.